MIRXES HOLDING PTE. LTD.

MiRXES is a Singapore-headquartered biotechnology company focused on developing and commercializing innovative diagnostic solutions for early, actionable, and personalized disease detection. With a strong presence in Asia and global ambitions, we have established research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. Our flagship product, GASTROClear, is a molecular blood test for early detection of gastric cancer, with plans to expand our cancer portfolio to include tests for lung, thyroid, colorectal, and breast cancer. Additionally, we are developing a precision oncology portfolio to provide clinical insights for the complete patient journey. Leveraging our versatile platform technology and capabilities, we aim to address unmet clinical needs in various disease areas, including cardiovascular, metabolic, and infectious diseases. In response to COVID-19, we have leveraged our capabilities to mass produce and distribute the Fortitude COVID-19 RT-PCR test, which has been deployed in multiple hospitals and clinical labs worldwide.